Introduction {#sec1-2055217318758119}
============

Aquaporin-4 (AQP4)-antibody-seropositive neuromyelitis optica (NMO) often affects women in their childbearing years. There have been only a few reports of acute-phase treatment in pregnant patients with seropositive NMO. ^[@bibr1-2055217318758119]^ In relapses of seropositive NMO, the first-line therapy is intravenous methylprednisolone (IVMP), and plasma exchange (PLEX) is a rescue therapy in those unresponsive to IVMP.^[@bibr1-2055217318758119]^ There are also several reports suggesting therapeutic efficacy of intravenous immunoglobulin (IVIg) in acute-phase NMO,^[@bibr2-2055217318758119][@bibr3-2055217318758119][@bibr4-2055217318758119][@bibr5-2055217318758119][@bibr6-2055217318758119]--[@bibr7-2055217318758119]^ but there are no reports of pregnant patients with seropositive NMO treated with IVIg as a rescue therapy.

Here we describe a pregnant woman who developed seropositive NMO following disseminated herpes zoster. She was refractory to IVMP but successfully treated with IVIg. We obtained the patient's written consent and the institutional review board's approval for publication.

Case report {#sec2-2055217318758119}
===========

The patient was a 26-year-old pregnant woman (gravida 3 partus 2). In May 2016, the patient felt burning pain over her neck, both arms and anterior chest. One week later, she had vesicular skin lesions with crusts and erosions suggestive of varicella zoster infection in those areas. After two more weeks, she had left hemiparesis that then progressed to quadriparesis. In her 17th week of pregnancy, the patient was referred to our hospital by a local obstetrician.

On admission, the patient was bedridden and could not even sit up. She had a high fever (38.8°C) and severe tingling pain below the neck level aggravated by minor stimuli, which was compatible with allodynia. She also had constipation lasting a week. Physical examination revealed oral candidiasis and vesicles accompanied by crusts and erosions over her right C4, bilateral C5--6 and left Th3 areas. Neurological examination showed profound quadriparesis (manual muscle strength of Medical Research Council 3/5 over the arms and 2/5 over the legs), generalized hyperreflexia, severe hypoesthesia in legs and bowel-bladder disturbance. Varicella-zoster virus (VZV) polymerase chain reaction and VZV-immunoglobulin M (IgM) were negative in the cerebrospinal fluid collected at the onset of myelitis. The patient also had hyponatremia (120 mEq/l) that was asymptomatic and resolved on day 8.

Brain and spinal magnetic resonance imaging (MRI) revealed a left hypothalamic T2-hyperintense lesion and a longitudinally extensive transverse lesion extending from the lower medulla down to Th6 ([Figure 1](#fig1-2055217318758119){ref-type="fig"}). However, she did not have dyspnea, hiccups or nausea/vomiting. The patient was treated with acyclovir (1500 mg/day) and heparin.

![(a) Spinal magnetic resonance imaging on day 2 exhibited a T2-hyperintense lesion extending from the medulla oblongata to the thoracic cord. (b) Axial image at the C1 level revealed an extensive lesion, mainly involving the central gray matter. (c) Axial image at the midbrain level showed a left hypothalamic lesion. (a) and (b): T2-weighted images. (c): Fluid-attenuated inversion recovery image.](10.1177_2055217318758119-fig1){#fig1-2055217318758119}

We suspected NMO at that point, and administered intravenous methylprednisolone (IVMP) (1 g/day for five days) on the day of admission. However, her symptoms deteriorated and she became completely paraplegic. Then, we treated her with intravenous immunoglobulin (IVIg) (0.4 mg/kg/day) rather than plasma exchange (PLEX) because of risks of suspected sepsis and circulatory instability affecting the fetus.

After IVIg was given on days 6 and 7, she developed a headache, and thus we discontinued the therapy. Although she barely moved her toes on day 7, she became able to raise her right knee on day 10. On day 13, serum AQP4-immunoglobulin G (IgG)) was found to be strongly positive (titers \> 75 U/ml), thus fulfilling the diagnostic criteria of NMO with AQP4-IgG.^[@bibr8-2055217318758119]^ The patient could not even brush her teeth on day 6 but was able to eat her meals without assistance on day 13. Then she received additional doses of IVIg from day 15 to day 17 with no side effects. Following this, she became able to raise her knees on day 16, dorsiflex her ankles on day 17 and stand up with assistance on day 21. She was given IVIg again from day 25 to day 29 and was able to walk with a walker on day 33. She needed laxatives and disimpaction for constipation and placement of an indwelling urinary catheter for urinary retention until day 29. But urinary and bowel symptoms improved thereafter and herpes zoster was epithelialized and scarred by day 33.

On day 41, she noticed left orbital pain and blurred vision. Her left visual acuity was 20/200 and upper altitudinal hemianopia was observed, indicating the development of left optic neuritis. Then, IVMP (1 g/day for five days) was given but she was refractory to it (20/400 in one week). She was then treated with the same doses of IVIg again but it had to be discontinued because of vomiting two days later. When she was discharged on day 70, she was able to read the headlines of a newspaper with remaining girdle sensation over the left T5 level. A month later, the patient gave birth at 37 weeks' gestation to a baby without any complications via spontaneous vaginal delivery. Her visual acuity gradually returned to normal although she still had the left T5 girdle sensation.

Discussion {#sec3-2055217318758119}
==========

Rescue therapy for severe NMO attacks refractory to IVMP in pregnant women with concomitant infections is not well established. There have been two cases of acute exacerbations of NMO in pregnancy that failed to respond to IVMP but were successfully treated with PLEX ([Table 1 (a)](#table1-2055217318758119){ref-type="table"}).^[@bibr1-2055217318758119],[@bibr9-2055217318758119]^ In our patient with corticosteroid-resistant NMO attacks, we chose IVIg rather than PLEX on the assumption that IVIg might also be effective for infections (disseminated herpes zoster, candidiasis and possible sepsis) as well as NMO. In fact, cases of infectious or parainfectious NMO/longitudinally extensive transverse myelitis (LETM) (mostly associated with herpes zoster) have been reported (Jarius S, et al. J Neurol Sci. 2009) and there are some reports on safety and efficacy of IVIG in immune-mediated diseases with concomitant infections (Simoes J, et al. J Clin Rheumatol. 2015).^[@bibr10-2055217318758119],[@bibr11-2055217318758119]^ Possible mechanisms of IVIG efficacy in NMO spectrum disorder may include modulations of AQP4-IgG binding and catabolism, complement activation and B-cell function (Wingerchuk DM. J Clin Immunol 2013). Moreover, IVIg is unlikely to cause circulatory instability adversely affecting the fetus, in contrast to PLEX. Despite short-term IVIg administrations because of adverse effects, the patient experienced significant neurological improvement of LETM while the improvement of optic neuritis was slower. IVIg has also been reported to be safe in neuroimmunological disorders such as myasthenia gravis and pregnancy.^[@bibr10-2055217318758119]^

###### 

\(a\) Case reports of therapeutic plasma exchange in AQP4-IgG-positive NMO during pregnancy and (b) case reports of intravenous immunoglobulin therapies in acute phase of AQP4-IgG-positive NMO.

![](10.1177_2055217318758119-table1)

  **Table 1 (a)**   **Age (gestation weeks)**   **Onset or relapse**   **Clinical symptoms and MRI findings**                       **Acute treatment before PLEX**     **Times of PLEX**                 **Effects of PLEX**             **Reference**
  ----------------- --------------------------- ---------------------- ------------------------------------------------------------ ----------------------------------- --------------------------------- ------------------------------- --------------------
  Case 1            25 (17)                     Relapse                Respiratory failure, cervical and thoracic LETM              Corticosteroids (unknown details)   Four times                        Complete recovery               Cornelio 2009
  Case 2            27 (20)                     Relapse                Paraplegia, cervical and thoracic LETM                       IVMP                                Five times                        Partial recovery                Rubio Tabares 2016
  **Table 1 (b)**   **Age, sex**                **Onset or relapse**   **Clinical symptoms and MRI findings**                       **Acute treatment before IVIg**     **IVIg**                          **Effects of IVIg**             **Reference**
  Case 3            49, F                       Onset                  Gait disturbance, myelitis from Th4 to Th6                   IVMP                                0.4 g/kg per day over five days   Complete recovery               Ii 2008
  Case 4            81, M                       Onset                  Paraplegia, myelitis from Th5 to Th11                        IVMP                                Unknown                           Complete recovery               Nakano 2009
                                                Relapse                Respiratory failure, LETM from medulla oblongata to C6       IVMP and IVIg                       Unknown                           No improvement                  Nakano 2009
  Case 5            32, F                       Onset                  Cognitive impairment, periventricular white matter lesions   IVMP                                0.4 g/kg per day over five days   Partial recovery                Stübgen 2012
  Case 6            37, M                       Onset                  Cognitive impairment, periventricular white matter lesions   IVMP                                0.4 g/kg per day over five days   Partial recovery                Stübgen 2012
  Case 7            28, F                       Relapse                ON                                                           IVMP                                Unknown                           Partial recovery                Romanelli 2014
  Case 8            66, F                       Onset                  ON and myelitis                                              Corticoids (unknown details)        Unknown                           Complete recovery               Hervás-García 2014
  Case 9            43, F                       Relapse                Respiratory failure, cervical myelitis                       None                                2 g/kg per day over five days     Partial recovery                Elsone 2014
  Case 10           38, F                       Relapse                Bilateral ON                                                 PLEX, oral PSL                      2 g/kg per day over five days     No improvement                  Elsone 2014
  Case 11           49, F                       Relapse                Paraplegia, thoracic LETM                                    IVMP                                2 g/kg per day over five days     No improvement                  Elsone 2014
  Case 12           40, F                       Relapse                Tetraplegia and heart failure, cervical LETM                 IVMP followed by oral PSL           2 g/kg per day over five days     Partial recovery                Elsone 2014
  Case 13           79, F                       Relapse                Tetraplegia, cervical LETM                                   IVMP followed by oral PSL           2 g/kg per day over five days     No improvement                  Elsone 2014
  Case 14           57, M                       Relapse                Tetraplegia, cervical and thoracic LETM                      IVMP                                2 g/kg per day over five days     Improved to baseline function   Elsone 2014
  Case 15           38, F                       Relapse                Tetraplegia, cervical LETM                                   IVMP, PLEX followed by oral PSL     2 g/kg per day over five days     Improved to baseline function   Elsone 2014
  Case 16           55, M                       Relapse                Bilateral ON                                                 Oral PSL                            2 g/kg per day over five days     No improvement                  Elsone 2014

AQP4: aquaporin 4; F: female; IgG: immunoglobulin G; IVIg: intravenous immunoglobulin; IVMP: intravenous methylprednisolone; LETM: longitudinally extensive transverse myelitis; ON: optic neuritis; M: male; MRI: magnetic resonance imaging; NMO: neuromyelitis optica; PLEX: plasma exchange; PSL: prednisolone.

In NMO, 14 cases (15 attacks) treated with IVIg as a rescue therapy have been reported in the literature and IVIg was efficacious in 10 attacks (Table 1 (b)).^[@bibr2-2055217318758119][@bibr3-2055217318758119][@bibr4-2055217318758119][@bibr5-2055217318758119][@bibr6-2055217318758119]--[@bibr7-2055217318758119]^ The main reason why IVIg was administered in those cases was unresponsiveness to IVMP or PLEX. In some patients unresponsive to IVIg, the median time from relapse to IVIg was longer than the intervals in those who responded to IVIg (3.5 months vs a week), suggesting early institution of IVIg is associated with better outcomes.^[@bibr7-2055217318758119]^ Owing to clinical deterioration during IVMP, IVIg was started without delay in our patient, which probably contributed to a favorable therapeutic response although a delayed effect of IVMP cannot be completely ruled out. Given that many women with seropositive NMO are of childbearing age, IVIg may be useful as rescue therapy in AQP4-IgG-positive NMO attacks refractory to IVMP in pregnant patients, especially when complicated with infectious diseases.
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